Bristol-myers Squibb Stock News

The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.

Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

If history is any guide, there may be good fortune ahead for shares of Bristol-Myers Squibb (NYSE: BMY ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO) said the U.S. Food and Drug

The U.S. Food and Drug Administration ((FDA)) granted priority review for expanded use of Bristol Myers Squibb''s (BMY) Breyanzi as a second line treatment of adults with relapsed…

Bristol Myers Squibb & Co (NYSE: BMY ) has announced interim results from the True North open-label extension study evaluating the long-term efficacy and safety of Zeposia (ozanimod) in active ulcerative colitis (UC). Findings show that the percentage of patients achieving clinical remission, clinical response, endoscopic improvement, and corticosteroid-free remission was maintained … Full story available on Benzinga.com

Bristol Myers Squibb & Co (NYSE: BMY) has announced interim results from the True North open-label extension study evaluating the long-term efficacy and safety of Zeposia (ozanimod) in active ulcer

I analyzed Eli Lilly and found it expensive, and decided to look at a peer.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. FDA Accepts for Priority Review BMS''s Supplemental Biologics License Application for Breyanzi as a Second-Line Therapy…

Bristol Myers Squibb: Bull Thesis Supported By Both Strong Technical And Fundamental Signals

Bristol-Myers Squibb Co. (BMY) shares closed today at 1.4% below its 52 week high of $68.59, giving the company a market cap of $147B. The stock is currently up 9.6% year-to-date, up 16.6% over the past 12 months, and up 41.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%. Trading Activity Trading volume this week was 67.4% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -536.5% The company's stock price performance over the past 12 months beats the peer average by 9.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -68.1% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE: BMY ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with BMY, it often means somebody knows something is about to happen. Today, Benzinga ''s options scanner spotted 15 options trades for Bristol-Myers Squibb . This isn''t normal. The overall sentiment of these big-money traders is split between 60% bullish and 40%, bearish. Out of all of the options we uncovered, there was 1 put, for a … Full story available on Benzinga.com

Bristol Myers Squibb Co''s (NYSE: BMY ) VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM) met its primary endpoint at Week 16 . The trial included symptomatic obstructive HCM patients who are eligible for septal reduction therapy (SRT). The safety of mavacamten was consistent with previous studies. "We look forward to sharing … Full story available on Benzinga.com